blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3632420

EP3632420 - TREATMENT OF FIBROSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.08.2024
Database last updated on 16.11.2024
FormerThe patent has been granted
Status updated on  25.08.2023
FormerGrant of patent is intended
Status updated on  20.04.2023
FormerExamination is in progress
Status updated on  02.12.2022
FormerRequest for examination was made
Status updated on  02.10.2020
FormerThe application has been published
Status updated on  06.03.2020
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): BG		published on 18.12.2024 [2024/51]
Applicant(s)For all designated states
The University Of Birmingham
Edgbaston, Birmingham B15 2TT / GB
[2020/15]
Inventor(s)01 / ABRAHAM, David
c/o The University of Birmingham
Edgbaston
Birmingham, B15 2TT / GB
02 / CALDER, Virginia
c/o The University of Birmingham
Edgbaston
Birmingham, B15 2TT / GB
03 / DALE, Sarah
c/o The University of Birmingham
Edgbaston
Birmingham, B15 2TT / GB
 [2020/15]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/39]
Former [2020/15]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19210155.801.05.2015
[2020/15]
Priority number, dateGB2014000780602.05.2014         Original published format: GB 201407806
[2020/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3632420
Date:08.04.2020
Language:EN
[2020/15]
Type: B1 Patent specification 
No.:EP3632420
Date:27.09.2023
Language:EN
[2023/39]
Search report(s)(Supplementary) European search report - dispatched on:EP04.03.2020
ClassificationIPC:A61K31/145, A61P27/02, A61K31/136
[2020/15]
CPC:
A61K31/145 (EP,US); A61K31/136 (EP,US); A61K8/411 (US);
A61K8/46 (US); A61K9/0048 (US); A61P27/02 (EP,US);
A61Q19/00 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/45]
Former [2020/15]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:BEHANDLUNG VON FIBROSE[2020/15]
English:TREATMENT OF FIBROSIS[2020/15]
French:TRAITEMENT DE LA FIBROSE[2020/15]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure28.09.2020Amendment by applicant (claims and/or description)
28.09.2020Examination requested  [2020/45]
28.09.2020Date on which the examining division has become responsible
02.12.2022Despatch of a communication from the examining division (Time limit: M04)
20.03.2023Reply to a communication from the examining division
21.04.2023Communication of intention to grant the patent
23.08.2023Fee for grant paid
23.08.2023Fee for publishing/printing paid
23.08.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15721030.3  / EP3137068
Opposition(s)28.06.2024No opposition filed within time limit [2024/36]
Fees paidRenewal fee
19.11.2019Renewal fee patent year 03
19.11.2019Renewal fee patent year 04
19.11.2019Renewal fee patent year 05
19.03.2020Renewal fee patent year 06
21.05.2021Renewal fee patent year 07
20.05.2022Renewal fee patent year 08
15.05.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT27.09.2023
BG27.09.2023
CZ27.09.2023
DK27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
IT27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SI27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
[2024/51]
Former [2024/49]AT27.09.2023
CZ27.09.2023
DK27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
IT27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SI27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
Former [2024/33]AT27.09.2023
CZ27.09.2023
DK27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
IT27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
Former [2024/26]AT27.09.2023
CZ27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
IT27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
Former [2024/25]AT27.09.2023
CZ27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
Former [2024/23]AT27.09.2023
CZ27.09.2023
EE27.09.2023
ES27.09.2023
FI27.09.2023
HR27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
RO27.09.2023
RS27.09.2023
SE27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
PT29.01.2024
Former [2024/20]FI27.09.2023
HR27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
RS27.09.2023
SE27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
Former [2024/14]FI27.09.2023
HR27.09.2023
LT27.09.2023
LV27.09.2023
NL27.09.2023
RS27.09.2023
SE27.09.2023
NO27.12.2023
GR28.12.2023
Former [2024/10]FI27.09.2023
HR27.09.2023
LT27.09.2023
LV27.09.2023
RS27.09.2023
SE27.09.2023
NO27.12.2023
GR28.12.2023
Former [2024/09]FI27.09.2023
LT27.09.2023
SE27.09.2023
NO27.12.2023
GR28.12.2023
Former [2024/08]LT27.09.2023
NO27.12.2023
GR28.12.2023
Documents cited:Search[A]WO9934784  (YEDA RES & DEV [IL], et al) [A] 1-7 * claims 1-3 *;
 [X]WO2007041593  (COMBINATORX INC [US], et al) [X] 1,2,4-6 * claim 6 *;
 [X]WO2008068746  (YEDA RES & DEV [IL], et al) [X] 1,2,4-6 * page 8, line 3 - line 20 *;
 [XI]CN103301097  (SHANGHAI CANCER INST) [X] 1,2,4-6 * paragraph [0016] - paragraph [0018] * * paragraph [0023] - paragraph [0029] * [I] 3,7;
 [A]  - V. KOPPAKA ET AL, "Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (20120701), vol. 64, no. 3, doi:10.1124/pr.111.005538, ISSN 0022-3565, pages 520 - 539, XP055246215 [A] 1-7 * page 532 *

DOI:   http://dx.doi.org/10.1124/pr.111.005538
 [XP]  - Dale S., "Aldehyde dehydrogenase as a novel and potential therapy for conjunctival fibrosis", (20141231), URL: http://discovery.ucl.ac.uk/1433170/, (20150710), XP002743863 [XP] 1-7 * the whole document *
by applicant   - KOPPAKA, Pharmacol Rev, (20120000), vol. 64, pages 520 - 539
    - BURTON et al., Infection and immunity, (20110000), vol. 79, pages 499 - 511
    - RAZZAQUE et al., Investigative ophthalmology and visual science, (20030000), vol. 44, pages 3417 - 3423,1616-1621
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.